Correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic Fibrosis in MASlD With type2 Diabetes Mellitus

Metabolic dysfunction asociated steatotic liver disease prevalence is 25%world wide diabetic patients have a risk for MASLD then have hepatic fibrosis so we study correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic fibrosis In Metabolic dysfunction asociated steatotic liver disease in patients with type2 Diabetes Mellitus

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Hepatic Fibrosis Digestive System Diseases Fibrosis Liver Cirrhosis Liver Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

30 year–65 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients of both sex who have type2 Diabetes Mellitus for less than five years

Exclusion criteria

alcholics ,chronic liver disease elevated liver functions , sever infection

Treatment and study plan

serum Adiponectine and Resistin

Diagnostic Test

corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis

FibroScan

Diagnostic Test

hepatic fibrosis detection in type 2 diabetes mellutis

Primary outcomes

degree of hepatic fibrosis in MASLD with type 2 diabetes mellitus

Time frame: 1 year

adiponectineand resistine level with degree of hepatic fibrosis in MASLD pt. with type 2 DM

Study contacts

Contact information is provided by the study sponsor or research team.

ELZAHRAA K Mohammed, spcialist

CONTACT

[email protected]

01064954825

usama M Abdelaal, professor

CONTACT

01065962094

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Correlation Between Serum Adiponectin and Resistin Levels and Degree of Hepatic Fibrosis In Metabolic Dysfunction _Associated Steatotic Liver Disease (MASLD)With Type2 Diabetes Mellitus

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Dec 4, 2024
Registry last updated: Dec 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting